Review ArticleReview Article
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease
Maryka Quik and Susan Wonnacott
Burt M. Sharp, ASSOCIATE EDITOR
Pharmacological Reviews December 2011, 63 (4) 938-966; DOI: https://doi.org/10.1124/pr.110.003269
Maryka Quik
Center for Health Sciences, SRI International, Menlo Park, California (M.Q.); and Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom (S.W.)
Susan Wonnacott
Center for Health Sciences, SRI International, Menlo Park, California (M.Q.); and Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom (S.W.)
Burt M. Sharp
Center for Health Sciences, SRI International, Menlo Park, California (M.Q.); and Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom (S.W.)
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
α6β2* AND α4β2* NACHRS: DRUG TARGETS FOR PARKINSON'S DISEASE
Maryka Quik and Susan Wonnacott
Pharmacological Reviews December 1, 2011, 63 (4) 938-966; DOI: https://doi.org/10.1124/pr.110.003269
Jump to section
- Article
- Abstract
- I. Introduction—Parkinson's Disease and Links to the Nicotinic Cholinergic System
- II. Inter-Relationship between Nicotinic Cholinergic and Dopaminergic Systems
- III. Neuronal Nicotinic Acetylcholine Receptors
- IV. Long-Term Regulation of Nicotinic Acetylcholine Receptors Expression and Function
- V. Role for Nicotine and Nicotinic Acetylcholine Receptor Ligands in Parkinson's Disease
- VI. Smoking, Nicotine, and Neuroprotection against Nigrostriatal Damage
- VII. Nicotine and Symptomatic Improvement
- VIII. Nicotine and l-DOPA-Induced Dyskinesias
- IX. Conclusion and Future Directions
- Acknowledgments
- Authorship Contributions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement